Linzess vs Motegrity
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Linzess | US Motegrity | |
|---|---|---|
| Generic name | linaclotide | prucalopride |
| Drug class | Guanylate Cyclase-C Agonist | Serotonin-4 Receptor Agonist |
| Treats | Irritable bowel syndrome with constipation, chronic constipation | Chronic idiopathic constipation |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | AbbVie/Ironwood | Takeda |
| Year approved | 2012 | 2018 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $140M | — |
| Common side effects | Diarrhea, Abdominal pain, Gas, Bloating | Headache, Abdominal pain, Nausea, Diarrhea |
Motegrity
Frequently asked questions
Is Linzess or Motegrity better?
Neither is universally "better." Linzess (linaclotide) and Motegrity (prucalopride) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Linzess and Motegrity?
Linzess is a Guanylate Cyclase-C Agonist made by AbbVie/Ironwood, while Motegrity is a Serotonin-4 Receptor Agonist made by Takeda. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Linzess has the larger estimated TV advertising budget of the two.